natgillin/translations-raw huggingface dataset:
EU/1/00/160/049 5 orodispersible tablets EU/1/00/160/050 6 orodispersible tablets EU/1/00/160/051 10 orodispersible tablets EU/1/00/160/052 12 orodispersible tablets EU/1/00/160/053 15 orodispersible tablets EU/1/00/160/054 18 orodispersible tablets EU/1/00/160/055 20 orodispersible tablets EU/1/00/160/056 30 orodispersible tablets EU/1/00/160/057 50 orodispersible tablets EU/1/00/160/058 60 orodispersible tablets EU/1/00/160/059 90 orodispersible tablets EU/1/00/160/060 100 orodispersible tablets 
EU/1/00/160/049 5 raspadljivih tableta za usta EU/1/00/160/050 6 raspadljivih tableta za usta EU/1/00/160/051 10 raspadljivih tableta za usta EU/1/00/160/052 12 raspadljivih tableta za usta EU/1/00/160/053 15 raspadljivih tableta za usta EU/1/00/160/054 18 raspadljivih tableta za usta EU/1/00/160/055 20 raspadljivih tableta za usta EU/1/00/160/056 30 raspadljivih tableta za usta EU/1/00/160/057 50 raspadljivih tableta za usta EU/1/00/160/058 60 raspadljivih tableta za usta EU/1/00/160/059 90 raspadljivih tableta za usta EU/1/00/160/060 100 raspadljivih tableta za usta
The safety and efficacy of Aerius 5 mg orodispersible tablets in children below the age of 12 years have not been established. 
Sigurnost i djelotvornost lijeka Aerius 5 mg raspadljive tablete za usta u djece mlađe od 12 godina nisu ustanovljene.
If you stop taking Aerius If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku, ljekarniku ili medicinskoj sestri.
Aerius 5 mg tablet desloratadine 
Aerius 5 mg tablete desloratadin
Adults and adolescents 12 years of age and over The recommended dose is one tablet once a day with water, with or without food. 
Odrasli i adolescenti u dobi od 12 ili više godina Preporučena doza je jedna tableta jedanput na dan, a uzima se s vodom, uz obrok ili natašte.
Name and address of the manufacturer responsible for batch release for oral solution 
Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet za oralnu otopinu
Each orodispersible tablet contains 2.5 mg desloratadine. 
Jedna raspadljiva tableta za usta sadrži 2,5 mg desloratadina.
The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine. 
U ispitivanjima provedenima s desloratadinom i loratadinom pokazalo se da oni nemaju kancerogenog potencijala.
Aerius 5 mg film-coated tablets desloratadine 
Aerius 5 mg filmom obložene tablete desloratadin
● seizures 
● omaglica
Each orodispersible tablet contains 5 mg desloratadine. 
Jedna raspadljiva tableta za usta sadrži 5 mg desloratadina.
How to take Aerius oral solution 
Kako uzimati Aerius oralnu otopinu
Aerius relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. 
Aerius ublažava simptome povezane s alergijskim rinitisom (upala nosnih puteva uzrokovana alergijom, na primjer, kod peludne groznice ili alergije na grinje) u odraslih osoba i adolescenata u dobi od 12 ili više godina.
Aerius 2.5 mg orodispersible tablets desloratadine 
Aerius 2,5 mg raspadljive tablete za usta desloratadin
Adults and adolescents 12 years of age and over The recommended dose is one tablet once a day with or without food. 
Odrasli i adolescenti u dobi od 12 ili više godina Preporučena doza je jedna tableta jedanput na dan, uz obrok ili natašte.
- The active substance is desloratadine 5 mg - The other ingredients of the tablet are calcium hydrogen phosphate dihydrate, microcrystalline cellulose, maize starch, talc. 
- Drugi sastojci su kalcijev hidrogenfosfat dihidrat, mikrokristalična celuloza, kukuruzni škrob, talk.
Aerius oral solution relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 1 year of age and older. 
Aerius oralna otopina ublažava simptome povezane s alergijskim rinitisom (upala nosnih puteva uzrokovana alergijom, na primjer, kod peludne groznice ili alergije na grinje) u odraslih osoba, adolescenata i djece u dobi od 1 ili više godina.
Exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses. 
Kada su liječeni dozama primjerenima za dob, izloženost desloratadinu bila je jednaka u odraslih i pedijatrijskih ispitanika koji sporo metaboliziraju desloratadin.
Aerius 2.5 mg orodispersible tablets 
Aerius 2,5 mg raspadljive tablete za usta
Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 6 years of age and older. 
Aerius raspadljiva tableta za usta ublažava simptome povezane s alergijskim rinitisom (upala nosnih putova uzrokovana alergijom, na primjer, kod peludne groznice ili alergije na grinje) u odraslih, adolescenata i djece u dobi od 6 ili više godina.
Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. 
Aerius raspadljiva tableta za usta ublažava simptome povezane s alergijskim rinitisom (upala nosnih putova uzrokovana alergijom, na primjer, kod peludne groznice ili alergije na grinje) u odraslih osoba i adolescenata u dobi od 12 ili više godina.
How to store Aerius oral solution 
Kako čuvati Aerius oralnu otopinu
Aerius 5 mg orodispersible tablets 
Aerius 5 mg raspadljive tablete za usta
Aerius 2.5 mg orodispersible tablet 
Aerius 2,5 mg raspadljiva tableta za usta
sodium citrate dihydrate, natural and artificial flavour (bubblegum), citric acid anhydrous, disodium edetate, purified water 
6.1 Popis pomoćnih tvari sorbitol propilenglikol sukraloza (E955) hipromeloza 2910 natrijev citrat, dihidrat prirodna i umjetna aroma (žvakaća guma) citratna kiselina, bezvodna dinatrijev edetat voda, pročišćena
If you take more Aerius than you should 
Međutim, ako uzmete više Aerius tableta nego
However, if you take more Aerius than you were told to, tell your doctor, pharmacist or nurse immediately. 
Vam je propisano, odmah o tome obavijestite svog liječnika, ljekarnika ili medicinsku sestru.
Aerius 5 mg orodispersible tablet 
Aerius 5 mg raspadljiva tableta za usta
Aerius 5 mg orodispersible tablets desloratadine 
Aerius 5 mg raspadljive tablete za usta desloratadin
● vomiting 
● povraćanje
Nervous system disorders 
Bolesnici s oštećenjem funkcije bubrega
Taking Aerius is not recommended if you are pregnant or nursing a baby. 
Ako ste trudni ili dojite, nije preporučljivo uzimati Aerius.
Hepatobiliary disorders 
Oralna otopina
Kit for radiopharmaceutical preparation 
Set za pripravu radiofarmaceutika.
Powder for solution for injection: 40 micrograms; 
Prašak za otopinu za injekciju: 40 mikrograma; reakcijski pufer: 1 ml
Reaction Buffer: vial (COP) 
Prašak: bočica (staklena); reakcijski pufer: bočica (COP)
Reaction Buffer: 1 ml 
mikrogram a
Body weight (kg) of dog 
Tjelesna težina (kg) psa
Over 40 kg 
Više od 40 kg
Any remaining half tablets should be discarded after 1 day. 
Sve preostale polovice tableta treba baciti nakon jednog dana.
ATCvet code: QC09BX90 
ATCvet kod: QC09BX90
In case of overdose the dog should be treated symptomatically. 
U slučaju predoziranja psa treba liječiti simptomatski.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 08/09/2015 
Datum prvog odobrenja: 08/09/2015
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži:
Shelf life of the veterinary medicinal product as packaged for sale: 18 months 
Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju: 18 mjeseci.
Interactions with other medicinal products and other forms of interaction: Inform the veterinary surgeon if the animal is taking, or has recently taken, any other medicines. 
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija Obavijestite veterinara ako životinja uzima, ili je nedavno uzimala, bilo koje druge veterinarskomedicinske proizvode.
The tablets can be divided into equal halves. 
Tablete se mogu podijeliti u jednake polovice.
The mean plasma protein binding in vitro is 93%. 
Prosječno vezivanje na proteine plazme in vitro iznosi 93 %.
Pharmacotherapeutic group: ACE inhibitors, combinations. 
FARMAKOLOŠKA SVOJSTVA Farmakoterapijska grupa: ACE inhibitori, kombinacije.
Any remaining half tablet should be placed back in the opened blister and stored (for a maximum of 1 day) in the original cardboard carton out of the sight and reach of children. 
Sve preostale polovice tableta treba vratiti u otvoreni blister i pohraniti (najviše 1 dan) u originalnoj kartonskoj kutiji izvan pogleda i dosega djece.
Further metabolic pathways are phase II, glucuronides and sulfates. 
Daljnji metabolički putovi su faza II, glukuronidi i sulfati.
Do not use during pregnancy and lactation (see section 4.7). 
Ne primjenjivati tijekom graviditeta i laktacije (vidjeti odjeljak 4.7).
ADVICE ON CORRECT ADMINISTRATION FORTEKOR PLUS tablets can be divided into halves if needed. 
SAVJETI ZA ISPRAVNU PRIMJENU FORTEKOR PLUS tablete mogu se prema potrebi podijeliti u polovice.
Iron oxide brown E172 
Smeđi željezov oksid E172
Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding. 
S obzirom da se bioraspoloživost smatra reduciranom kada se pimobendan primjenjuje s hranom ili neposredno nakon jela, preporučuje se tretirati životinje približno sat vremena prije hranjenja.
The table below may be used for guidance. 
Tablica u nastavku može se koristiti kao smjernica.
Store below 25 °C. 
Čuvati pri temperaturi do 25°C.
However, these effects are dose-dependent and can be avoided by reducing the dose in those cases. 
Međutim, ti učinci ovise o dozi i mogu se izbjeći smanjenjem doze.
Ask your veterinary surgeon or your pharmacist how to dispose of medicines no longer required. 
Pitajte vašeg veterinara ili farmaceuta kako odlagati veterinarsko-medicinske proizvode koji vam više nisu potrebni.
Do not use in pregnant or lactating dogs (see section “SPECIAL WARNINGS"). 
Ne primjenjivati na gravidnim ili kujama u laktaciji (vidjeti odjeljak „POSEBNA UPOZORENJA“).
Dose and treatment schedule: 
Doziranje i raspored liječenja
Evening 
Uvečer
- very rare (less than 1 animal in 10,000 animals, including isolated reports). 
- vrlo rijetke (manje od 1 životinje na 10 000 životinja, uključujući izolirane slučajeve)
Both tablet strengths are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. 
Tablete obje jakosti pakirane su u blistere aluminij/aluminij koji su umetnuti u vanjsku kartonsku kutiju.
FORTEKOR PLUS tablets should be administered orally, twice daily 12 hours apart (morning and evening) and approximately 1 hour before feeding. 
FORTEKOR PLUS tablete treba primjenjivati peroralno, dva puta na dan u razmaku od 12 sati (ujutro i uvečer) te približno sat vremena prije hranjenja.
EXP {month/year} 
ROK VALJANOSTI EXP: {mjesec/godina}
MINIMUM PARTICULARS TO APPEAR ON BLISTERS Blister 
OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA BLISTERIMA
Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans. 
Trudnice trebaju posebno paziti da izbjegnu slučajno oralno izlaganje jer je otkriveno da inhibitori enzima koji konvertiraju angiotenzin (ACE) utječu na nerođeno dijete tijekom trudnoće u ljudi.
After oral administration of benazepril hydrochloride alone, the systemic bioavailability is incomplete (~13%) in dogs due to incomplete absorption (38%) and first pass metabolism. 
Nakon peroralne primjene samog benazepril hidroklorida, sistemska bioraspoloživost nije potpuna (~ 13 %) u pasa zbog nepotpune apsorpcije (38 %) te metabolizma prvog prolaza.
Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2 = 1.7 h) represents elimination of the free drug, while the terminal phase (t1/2 = 19 h) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. 
Koncentracije benazeprilata opadaju bifazično: početna brza faza (t1/2 = 1,7 h) predstavlja eliminaciju slobodnog lijeka, dok terminalna faza (t1/2 = 19 h) odražava oslobađanje benazeprilata koji je bio vezan na ACE, uglavnom u tkivima.
Keep the blister in the outer carton in order to protect from moisture. 
Čuvati blister u vanjskoj kutiji radi zaštite od vlage.
The efficacy and safety of the product has not been established in dogs below 2.5 kg body weight or under 4 months of age. 
Djelotvornost i neškodljivost proizvoda nisu utvrđene u pasa ispod 2,5 kg tjelesne težine ili mlađih od
A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs. 
Umjereni porast u plazmatskim koncentracijama kreatinina nakon primjene ACE inhibitora kompatibilan je s redukcijom glomerularne hipertenzije koju uzrokuju ti lijekovi i stoga nije nužno razlog za prekid terapije u odsutnosti drugih znakova.
White and light brown oval bilayer tablets with a score line on both sides. 
Bijele i svijetlosmeđe ovalne dvoslojne tablete s razdjelnom crtom na obje strane.
Repeated administration of benazepril hydrochloride leads to slight bioaccumulation of benazeprilat (R = 1.47), steady state being achieved within a few days (4 days). 
Ponovljena primjena benazepril hidroklorida dovodi do blage bioakumulacije benazeprilata (R = 1,47), dok se stabilno stanje postiže unutar nekoliko dana (4 dana).
60 tablets 
30 tableta 60 tableta
Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after EXP. 
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na blisteru i kutiji poslije „EXP“.
It also exhibits a vasodilatory action through the inhibition of phosphodiesterase type III activity. 
Također iskazuje vazodilatatorsko djelovanje kroz inhibiciju aktivnosti fosfodiesteraze tipa III.
In dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy. 
U pasa s kroničnom bolešću bubrega, benazepril može povisiti plazmatske koncentracije kreatinina na početku terapije.
Benazeprilat is excreted via the biliary (54%) and urinary (46%) routes in dogs. 
Benazeprilat se u pasa izlučuje putem žuči (54 %) te urinom (46 %).
The tablets are bilayered, oval, white and light brown, and can be divided into halves along the score line. 
Tablete su dvoslojne, ovalne, bijele i svijetlosmeđe te se mogu podijeliti na polovice duž razdjelne crte.
FORTEKOR PLUS is a fixed combination product which should only be used in dogs which require both active substances to be administered concomitantly at this fixed dose. 
FORTEKOR PLUS je proizvod fiksne kombinacije koji se smije primjenjivati samo u pasa koji zahtijevaju istovremenu primjenu obje djelatne tvari u ovoj fiksnoj dozi.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 
Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s propisima o zbrinjavanju otpada.
Peak benazeprilat levels are seen after 1.9 h with peak concentrations (Cmax) of 43.4 ng/ml. 
Vršne razine benazeprilata uočene su nakon 1,9 h s maksimalnim koncentracijama (Cmax) od 43,4 ng/ml.
People with known hypersensitivity to pimobendan or benazepril hydrochloride should avoid contact with the veterinary medicinal product. 
Osobe preosjetljive na pimobendan ili benazepril hidroklorid trebaju izbjegavati kontakt s veterinarsko-medicinskim proizvodom.
The volume of distribution at steady state is 2.6 l/kg after intravenous administration of pimobendan alone, indicating that pimobendan is distributed readily into the tissues. 
Volumen distribucije u stabilnom stanju iznosi 2,6 l/kg nakon intravenske primjene samog pimobendana, što ukazuje na to da se pimobendan lako distribuira u tkiva.
FORTEKOR PLUS is a fixed dose combination and should only be used in patients whose clinical signs are successfully controlled by administration of the same doses of the individual components (pimobendan and benazepril hydrochloride) given concurrently. 
FORTEKOR PLUS je kombinacija fiksne doze i smije se koristiti samo u pasa kod kojih su klinički znakovi uspješno kontrolirani primjenom istih doza pojedinačnih komponenti (pimobendan i benazepril hidroklorid) koje se daju istovremeno.
Following oral administration of pimobendan alone the absolute bioavailability of the active ingredient is 60-63%. 
Nakon peroralne primjene samog pimobendana, apsolutna bioraspoloživost djelatne tvari je 6063 %.
Therefore, benazepril blocks effects mediated by angiotensin II and aldosterone, including the vasoconstriction of arteries and veins, the retention of sodium and water by the kidney, and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes). 
Stoga benazepril blokira učinke posredovane angiotenzinom II i aldosteronom, uključujući vazokonstrikciju arterija i vena, retenciju natrija i vode u bubrezima i učinke remodeliranja (uključujući patološku, srčanu hipertrofiju i degenerativne promjene na bubrezima).
It increases the calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III). 
On povećava osjetljivost na kalcij srčanih miofilamenata i inhibira fosfodiesterazu (tip III).
The combination of FORTEKOR PLUS and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. 
Kombinacija FORTEKORA PLUS i drugih antihipertenziva (npr. blokatora kalcijevih kanala, β blokatora ili diuretika), anestetika ili sedativa može uzrokovati dodatne hipotenzivne učinke.
In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. 
U farmakološkim ispitivanjima nisu uočene interakcije između srčanog glikozida ouabaina i pimobendana.
In dogs with congestive heart failure, benazepril hydrochloride and pimobendan have been given in combination with digoxin and diuretics without demonstrable adverse interactions. 
U pasa s kongestivnim zatajenjem srca, benazepril hidroklorid i pimobendan daju se u kombinaciji s digoksinom i diureticima bez dokazivih štetnih interakcija.
After the oral administration of FORTEKOR PLUS tablets at twice the recommended dose to dogs, peak levels of both compounds are attained rapidly (Tmax 0.5 h for benazepril hydrochloride and 0.85 h for pimobendan) with peak concentrations (Cmax) for benazepril hydrochloride of 35.1 ng/ml and 16.5 ng/ml for pimobendan. 
Nakon peroralne primjene tableta FORTEKOR PLUS pri dvostruko preporučenoj dozi na psima, vršne razine obje komponente postižu se brzo (Tmax 0,5 h za benazepril hidroklorid i 0,85 h za pimobendan) s maksimalnim koncentracijama (Cmax) od 35,1 ng/ml za benazepril hidroklorid i 16,5
FORTEKOR PLUS is a combination of 2 active substances: pimobendan and benazepril hydrochloride. 
FORTEKOR PLUS je kombinacija dvije djelatne tvari: pimobendana i benazepril hidroklorida.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue. 
Kod manjeg broja pasa može se pojaviti prolazno povraćanje, nedostatak koordinacije ili znakovi umora.
It is not known if benazepril is secreted into the milk of lactating bitches. 
Nije poznato izlučuje li se benazepril u mlijeko kuja u laktaciji.
26 Rue de la Chapelle F-68330 Huningue 
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue FRANCUSKA
The plasma elimination half-life of pimobendan when dosed with FORTEKOR PLUS tablets is 0.5 h, consistent with the high clearance of the compound. 
Poluživot eliminacije pimobendana iz plazme, kada se dozira tabletama FORTEKOR PLUS, iznosi 0,5 h, što je u skladu s visokim klirensom spoja.
In cases of chronic kidney disease, it is recommended to check the dog's hydration status before starting therapy, and to monitor its plasma creatinine and blood erythrocyte counts during therapy. 
U slučajevima kronične bolesti bubrega preporučuje se provjeriti status hidracije psa prije početka terapije te nadzirati kreatinin u plazmi i broj eritrocita u krvi tijekom terapije.
Pimobendan/Benazepril hydrochloride 
Pimobendan/benazepril hidroklorid
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the ß-antagonist propranolol. 
Povećanje kontraktilnosti srčanog mišića uzrokovano pimobendanom oslabljeno je u prisutnosti kalcijevih antagonista verapamila i β-antagonista propranolola.
Your veterinary surgeon may therefore recommend the monitoring of plasma potassium concentrations when using FORTEKOR PLUS in combination with a potassium-sparing diuretic because of the risk of hyperkalaemia (high blood potassium). 
Vaš veterinar može stoga preporučiti praćenje koncentracija kalija u plazmi prilikom primjene FORTEKORA PLUS u kombinaciji s diureticima koji štede kalij zbog rizika od hiperkalijemije (visoke razine kalija u krvi).
Do not use during pregnancy or lactation. 
Ne primjenjivati tijekom graviditeta ili laktacije.
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic or pulmonary stenosis). 
Ne primjenjivati u slučajevima hipertrofične kardiomiopatije ili kod kliničkih stanja kod kojih nije moguće povećanje istisne funkcije srca zbog funkcionalnih ili anatomskih razloga (primjerice, stenoza aorte ili plućne arterije).
Do not use in cases of hypotension (low blood pressure), hypovolemia (low blood volume), hyponatraemia (low blood sodium levels) or acute renal (kidney) failure. 
Ne primjenjivati u slučajevima hipotenzije (niskog krvnog tlaka), hipovolemije (niskog volumena krvi), hiponatrijemije (niske razine natrija u krvi), ili akutnog renalnog zatajenja (zatajenja bubrega).
Your veterinary surgeon may recommend to closely monitor kidney function and for signs of hypotension (lethargy, weakness etc) and treat these if necessary. 
Vaš veterinar može preporučiti pažljivo praćenje funkcije bubrega i znakova hipotenzije (letargija, slabost itd.) te prema potrebi liječiti iste.
Benazepril increased the time to worsening of heart failure, and the time to death, improved clinical condition, reduced cough and improved exercise tolerance in dogs with symptomatic congestive heart failure caused by valvular disease or dilated cardiomyopathy. 
Benazepril je produljio vrijeme do pogoršanja zatajenja srca i vrijeme do smrti, poboljšao je kliničko stanje, smanjio je kašalj i poboljšao podnošenje napora u pasa sa simptomatskim kongestivnim zatajenjem srca uzrokovanim bolešću zalistaka ili dilatacijskom kardiomiopatijom.
EU/2/15/185/001 (1 x 30 tablets, 1.25 mg/2.5 mg tablets) EU/2/15/185/002 (1 x 60 tablets, 1.25 mg/2.5 mg tablets) EU/2/15/185/003 (1 x 30 tablets, 5 mg/10 mg tablets) EU/2/15/185/004 (1 x 60 tablets, 5 mg/10 mg tablets) 
EU/2/15/185/001 (1 x 30 tableta, 1,25 mg/2,5 mg tableta) EU/2/15/185/002 (1 x 60 tableta, 1,25 mg/2,5 mg tableta) EU/2/15/185/003 (1 x 30 tableta, 5 mg/10 mg tableta) EU/2/15/185/004 (1 x 60 tableta, 5 mg/10 mg tableta)
Each tablet contains 5 mg pimobendan and 10 mg benazepril hydrochloride. 
Svaka tableta sadrži 5 mg pimobendana i 10 mg benazepril hidroklorida.